Funding
Researcher : Assunta Cirella
4 funding - 1,047,728€
2021
-
Desarrolo preclínico y translacional de una estrategia inmunoterapia intratumoral consitente en la combinacion de BO-112 STING
euro 126,500.00
-
Integrating 4-1BB (CD137) agonists, interleukin-12, interleukin-18 and TGFb; antagonists in synergistic combined cancer
euro 459,800.00
-
INTERLEUKIN-8 AND NEUTROPHIL EXTRACELLULAR TRAPS AS ACTIONABLE TARGET AND BIOMARKERS FOR CANCER IMMUNOTHERAPY
euro 213,555.00
2018
-
H2020-ITN Tumor Treg Targeting
euro 247,873.00